FDA Grants Compassionate Use Authorization for Urcosimod 0.05% in Neuropathic Corneal Pain Treatment

The U.S. Food and Drug Administration (FDA) has authorized the compassionate use of Urcosimod 0.05%, a novel topical treatment, for patients suffering from neuropathic corneal pain, effective January 23, 2026. This decision follows positive interim trial results demonstrating significant pain reduction in affected individuals. The drug, developed by an undisclosed biotech firm, is currently not FDA-approved for general use but may provide relief to those with severe, unmanageable symptoms. Industry analysts suggest this move could expedite broader approval if further clinical trials confirm efficacy and safety. Shares of the unnamed developer remain closed until formal announcement.